KRYSライブシグナル | Getagraph.comで利益を最大化

売る 5739 min ago

@ $156.83

発行日: 26 4月 2024 @ 02:04

リターン: 2.46%

前回のシグナル: 4月 24 - 04:53

前回のシグナル: 買う

リターン: -3.12 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States...

Stats
本日の出来高	71 535.00
平均出来高	392 008
時価総額	4.55B
EPS	$0 ( 2024-02-26 )
次の収益日	( $0.280 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	412.03
ATR14	$2.05 (1.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	Krishnan Suma	Sell	2 146	Common Stock
2024-03-11	Krishnan Suma	Sell	2 254	Common Stock
2024-03-11	Krishnan Suma	Sell	5 109	Common Stock
2024-03-11	Krishnan Suma	Sell	8 002	Common Stock
2024-03-11	Krishnan Suma	Sell	2 816	Common Stock

INSIDER POWER
4.49
Last 100 transactions
Buy: 214 300 \| Sell: 194 377

ボリューム相関

長: -0.57 (weak negative)

短: -0.44 (neutral)

Signal:(61) Neutral

Krystal Biotech Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Krystal Biotech Inc 相関 - 通貨/商品

-0.30
( neutral )

0.59
( weak )

0.29
( neutral )

0.10
( neutral )

-0.76
( moderate negative )

0.48
( neutral )

Krystal Biotech Inc 財務諸表

Annual	2023
収益:	$50.70M
総利益:	$42.60M (84.02 %)
EPS:	$0.400

FY	2023
収益:	$50.70M
総利益:	$42.60M (84.02 %)
EPS:	$0.400

FY	2022
収益:	$0
総利益:	$-4.05M (0.00 %)
EPS:	$-5.49

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.13

Financial Reports:

No articles found.

Krystal Biotech Inc

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.